Chronic, low-dose treatment of male rats with cyclophosphamide, a chemotherapeutic agent, is known to affect progeny outcome adversely in a dose-dependent and time-specific manner, resulting in increased pre-and postimplantation loss as well as malformations. Concern exists regarding the genetic quality of mature gametes exposed to cyclophosphamide during mitosis and meiosis. The goal of the present study was to determine the effect of chronic cyclophosphamide treatment during spermatogenesis on the frequency of numerical chromosomal anomalies in epididymal spermatozoa. Male rats were treated with either saline or cyclophosphamide (6 mg kg Ϫ1 day
INTRODUCTION
Aneuploidies are the most serious and frequent chromosomal defects in humans. Numerical chromosomal abnormalities are associated with congenital defects [1] and are critical in both the early initiation stages and the progression of a wide array of malignant tumors [2] . An ab- normal chromosome complement can be transmitted to the progeny from either the mother or the father and can profoundly affect the viability, health, and development of the embryo. Pregnancies involving numerical abnormalities for chromosomes 13, 18, 21 , X, and Y survive to term and account for approximately 0.3% of newborns who remain affected, making aneuploidy the leading known genetic cause of physical disabilities and mental retardation [3, 4] .
In general, autosomal aneuploidies represent major maternal contributions, whereas the paternal contributions are reflected more frequently in the sex chromosomes. At birth, paternal meiotic error contributes to all XYY cases, to 80% of cases of sex chromosome monosomy for Turner syndrome (XO), and to approximately half of Klinefelter syndrome (XXY) cases [3, 4] . Although the incidence and consequence of aneuploidy in humans has been well documented, the events and mechanisms that may lead to the induction of aneuploidy in germ cells remain poorly understood. Consequently, aneuploidy is an important genetic peril in human reproduction and a focus for research into genotoxicity and mechanisms of induction [3, 5] .
Preconceptional paternal drug exposure is a source of detrimental effects on the genetic makeup and well-being of the embryo and infant [6] . The recent availability of sperm fluorescence in situ hybridization (FISH) with chromosome-specific DNA probes makes it possible to analyze spermatozoal samples from both exposed and unexposed individuals with the advantage of rapidly and accurately generating large data sets [7] . Using FISH, the frequency of numerical chromosomal abnormalities in both normal [8] [9] [10] and infertile men [11, 12] as well as increased incidences of aneuploid spermatozoa among cigarette smokers [13] , following consumption of caffeine and alcohol [14] , and after drug and pesticide exposure [15] [16] [17] have been established.
Animal studies offer the advantage that specific windows of toxicant exposure may be assessed to deduce the susceptibility of specific germ cell stages to potential aneugens and to elucidate the mechanisms by which genotoxic damage occurs during spermatogenesis. Consequently, FISH has been extended and optimized for use in mice [18, 19] , rats [20] , and pigs [21] . The mouse epididymal sperm FISH assay for aneuploidy was used to examine the sensitivity of the assay in detecting aneuploidy and diploidy following treatment of male mice with a number of test chemicals (for review, see [22] ) and has provided evidence that the sperm FISH assay is able to bridge the gap between humans and rodents [23] .
Chemotherapeutic agents were observed to be gonadotoxic in a dose-dependent and time-specific manner, rendering a proportion of cancer survivors with persistent oligozoospermia or azoospermia (for review, see [24] ). Recent FIG. 1. Schematic presentation of male germ cell differentiation during rat spermatogenesis. From timing the period of cyclophosphamide exposure, germ cell phase-dependent susceptibility can be characterized. Drug administration by gavage for 6 wk initially targets pachytene spermatocytes, whereas a 9-wk treatment initially targets spermatogonia. For each treatment regime, rats were treated chronically (6 mg kg Ϫ1 day Ϫ1 ), and cauda epididymal spermatozoa were analyzed by rat sperm Y-4 FISH.
data demonstrating that aneuploid spermatozoa were as competent as normal spermatozoa for fertilization and progression to the first cell cycle of zygotic development [25, 26] underline the concern regarding the potential for adverse progeny outcome because of germ cell mutagenesis following natural conception. Paternal drug exposure leading to increased DNA damage, structural aberrations, and aneuploidy in the spermatozoa can be heritably transmitted, resulting in an increased incidence of offspring with chromosomal abnormalities [26] . Evidence that genetically damaged spermatozoa are capable of accomplishing fertilization naturally [25, 26] or after intracytoplasmic sperm injection [27] has tremendous implications for cancer survivors, emphasizing the need to further assess the induction of genetic damage following exposure to commonly used chemical toxicants.
Cyclophosphamide, a bifunctional alkylating agent, is extensively used as an anticancer chemotherapeutic agent for childhood [24, 28] and adult malignancies [29] and as an immunosuppressive agent for organ transplantation, systemic lupus erythematosus, glomerulonephritis, multiple sclerosis, and other benign diseases [29] . Cyclophosphamide targets rapidly dividing cells, disrupting cell growth, mitotic activity, differentiation, and functions via alkylation of DNA at the N7 position of guanine [29, 30] . The cytotoxicity mediated by the formation of DNA-DNA crosslinks, DNA-protein cross-links, and single-strand breaks is greater than for other drugs; however, many damaged cells survive exposure to cyclophosphamide [29, 30] .
The complex, sequential stages of differentiation and chromosomal assortment make male germ cells highly vulnerable to chemicals that interact with DNA [31, 32] . A number of studies have confirmed that cyclophosphamide is a DNA-damaging agent during spermatogenesis. Exposure of rat spermatocytes to cyclophosphamide resulted in synaptic failure, fragmentation of the synaptonemal complex, and altered centromeric DNA sequences [33] . Cyclophosphamide also induced gene conversions and frameshift mutations in spermatocytes, indicating a genotoxic effect on the genome during meiotic prophase [34] . Furthermore, chronic paternal cyclophosphamide exposure revealed a dose-dependent and time-specific increase in pre-and postimplantation loss as well as impaired embryonic development and birth defects [35] [36] [37] . These adverse effects on progeny raise concerns regarding the effect of cyclophosphamide treatment on the genetic quality of the mature male gamete. Therefore, the goal of the present study was to establish whether chronic cyclophosphamide treatment, given in a clinically relevant dose, results in chromosomal anomalies, such as aneuploidy or diploidy, in rat spermatozoa.
MATERIALS AND METHODS

Animal Treatments
Adult male Sprague-Dawley rats (body wt, 350-400 g) were purchased from Charles River Canada (St. Constant, QC, Canada) and housed at the McIntyre Animal Resources Centre, McGill University. Rats were maintained on a 12L:12D photoperiod and received food and water ad libitum. One week after arrival, males were randomly assigned to one of two treatment groups of 10 animals each and gavaged with either saline or 6 mg kg Ϫ1 day Ϫ1 cyclophosphamide (CAS 6055-19-2; Sigma Chemical Co., St. Louis, MO) six times per week for either 6 or 9 wk. The selected treatment regimen targets two separate phases of spermatogenesis: (1) cyclophosphamide administration for 6 wk ensures that the first cells to be exposed are pachytene spermatocytes through to cauda epididymal spermatozoa; (2) cyclophosphamide administration for 9 wk first exposed spermatogonial germ cells throughout spermatogenesis to cauda epididymal spermatozoa. Thus, the selected treatment times allowed specific targeting of meiotic (6-wk) and mitotic (9-wk) germ cells, respectively ( Fig. 1 ). Rats were killed 1 day subsequent to the completion of each treatment regime by CO 2 inhalation and decapitation. All animal protocols were conducted in accordance with the guidelines outlined in the Guide to the Care and Use of Experimental Animals, prepared by the Canadian Council on Animal Care.
Isolation of Epididymal Spermatozoa and Slide Preparation
Cauda epididymal spermatozoa were isolated following the procedure described by Lowe et al. [18] with minor modifications. Briefly, the epididymides were removed surgically, trimmed free of fat, and placed in 2.2% sodium citrate (prewarmed to 37ЊC) to remove any excess debris. Each epididymis was clamped with a hemostat at the corpus-cauda junction, and an incision through several tubule segments was made in the distal cauda epididymis using a no. 11 scalpel blade. The region of the incision was then gently rinsed in 0.6 ml of 2.2% sodium citrate at 37ЊC to allow the spermatozoa to swim out of the epididymis. The spermatozoal suspension was separated into five 100-l aliquots, immediately frozen in liquid nitrogen, and stored at Ϫ80ЊC until shipped to Lawrence Livermore National Laboratory (LLNL) on dry ice for subsequent slide preparation and FISH. Spermatozoal smears were prepared as previously described [20] . Each slide was evaluated using a phase-contrast microscope to ensure the sample preparation and spermatozoal concentration in the smears from the saline-and cyclophosphamide-treated rats were indistinguishable. The most uniform set of slides was selected for hybridization. All slides were coded before hybridization by an individual who was not involved in the analysis. Smears not used for hybridization were stored in nitrogen gas at Ϫ20ЊC until used.
Pretreatment and FISH of Spermatozoa
Smears of rat spermatozoa were each fixed in 3:1 methanol:acetic acid and air-dried before commencing pretreatment. To prepare the smears for rat FISH, spermatozoa were decondensed by incubating the slides in a Coplin jar for 30 min in 10 mM dithiothreitol (Sigma) on ice, allowing the maintenance of spermatozoal head and tail structure. Slides were briefly rinsed in ddH 2 O and allowed to dry completely at room temperature before they were used for hybridization. The methods used for hybridizations were previously described by Lowe et al. [18, 20] and were followed with minor modifications. Briefly, the spermatozoa on each slide were denatured in 70% formamide/2ϫ SSC (single strength: 0.15 M sodium chloride and 0.015 sodium citrate), pH 7.0, at a temperature of 78ЊC for 2 min and then dehydrated in an ice-cold alcohol series. The probe mixture, containing DNA probes specific for rat chromosomes 4 (25S5) and Y (9.1ES8), as previously described [20, 38] , was denatured at 78ЊC for 10 min. Denatured hybridization mix (10 l) was immediately applied to the air-dried spermatozoal smears and incubated for 24-48 h in a moist chamber at 37ЊC. Five posthybridization washes were carried out at 45ЊC for 5 min each: three times in 50% formamide/2ϫ SSC, pH 7.0; once in 2ϫ SSC; and once in PN buffer (0.1M NaH 2 PO 4 /0.1 M Na 2 HPO 4 , pH 8.0, and 0.1% Nonidet P-40 [Sigma] ). The posthybridization washes were completed by a 5-min incubation in PN buffer at room temperature. The probes for chromosomes 4 and Y were visualized by fluorescein isothiocyanate (FITC)-avidin and rhodamine-antidigoxigenin, respectively, using 30 l of Biotin-Digoxigenin Dual Colour Detection Kit (Oncor, Gaithersburg, MD). Spermatozoal nuclei were counterstained with 0.01 g/ml of 4,6-diamidino-2-phenylindole (DAPI) in Vectasheild mounting medium (Vector Laboratories, Burlingame, CA).
Scoring of Hybridized Spermatozoal Smears
All hybridized slides were coded, recoded, and decoded by an individual who was not involved in scoring. Descriptions of the spermatozoa scored were recorded using the CYTOscore program developed at LLNL for utility with the human and rodent sperm FISH assays. At least 10 000 cells were scored for each of the 20 animals (five rats for each of the cyclophosphamide and saline groups treated for 6 and 9 wk) for a total of 200 716 spermatozoa. Slides were independently scored using a fluorescent photomicroscope equipped with a double band-pass filter for the simultaneous visualization of red (rhodamine) and green (FITC) hybridization signals, single fluorochrome filters for confirmation of individual color domains (rhodamine, 41002C HQ:R; FITC, 41001 HQ:F; Chroma Technology Corp., Brattleboro, VT), as well as a filter for blue fluorescence (DAPI) used to identify spermatozoal nuclear counterstain. Phase-contrast was used to confirm the location of signals within the boundaries of the spermatozoal nucleus as well as to detect the presence of debris. Spermatozoa that were disrupted or overlapping were excluded from the analysis. The hybridization efficiency was greater than 99.9% across all slides, and spermatozoa were equally decondensed such that no difference was observed between treated and control samples. Photographic images were captured using a RS Photometrics CoolSNAP fx camera (Roper Scientific, Tucson, AZ) and imported into CorelDRAW9 (Corel Corporation, Ottawa, ON, Canada).
The spermatozoa were classified according to the specific combination of fluorescent signals observed in each nucleus as previously described [20] . [18] .
Morphological characteristics of the chromosomally abnormal spermatozoa were recorded simultaneously with the scoring of chromosomal abnormalities on the hybridized slides. Each genotypically abnormal spermatozoon was scored as morphologically normal in the presence of a hook-shaped head equal in size to spermatozoa with normal fluorescent genotypes (Y-4, 0-4). Atypical forms were classified by head-shape abnormalities, such as amorphous head, enlarged head, or double head [39] . Differences in spermatozoal head size and shape were confirmed using phase-contrast, and nuclei were measured with an ocular micrometer (100ϫ objective).
Statistical Analysis
Chi-square analyses were employed to compare the frequencies of aneuploid and diploid spermatozoa observed from control animals with those treated chronically with cyclophosphamide (P Ͻ 0.05). Statistical analyses were done using SigmaStat 2.03 software package (SPSS, Inc., Chicago, IL).
RESULTS
The ability of chronic cyclophosphamide treatment to induce aneuploidy in rat epididymal spermatozoa was evaluated using the dual-color rat Y-4 sperm FISH assay previously developed and optimized by Lowe et al. [20] . The number and color of fluorescent DNA probes specific for chromosome 4 (FITC) and chromosome Y (Digoxigenin, DIG) determined the phenotype of each spermatozoon. Cytogenetically normal and abnormal spermatozoa are illustrated in Figure 2 . Spermatozoa with a single green domain (0-4) or a single green and a single red domain (Y-4) presumably represent chromosomally normal cells (Fig. 2A) . Of the 200 716 spermatozoa analyzed, 49 .69% displayed a Y-4 phenotype, whereas 50.14% of the cells carried the 0-4 phenotype. Presumably, these latter cells were carrying an unlabeled X chromosome. Thus, the ratio of X-bearing spermatozoa to Y-bearing spermatozoa was approximately 1, as expected, for all animals analyzed (Table 1) . Spermatozoa with other combinations of colored domains represent spermatozoa with numerically abnormal genotypes and were assigned to the categories of disomy (Fig. 2, B-D) , nullisomy (Fig. 2E), or autodiploidy (Fig. 2F) .
Analyses of the aneugenic effect of cyclophosphamide treatment are presented in Table 1 . Treatment with 6.0 mg kg Ϫ1 day Ϫ1 of cyclophosphamide for 6 wk did not induce significant changes in the frequency of hyperhaploid spermatozoa for either chromosome 4 or chromosome Y. However, a 2.3-fold increase in frequency was observed for one of the subcategories of disomy 4 (Y-4-4), but not for the other subcategory or for nullisomy 4. After 6 wk of treatment, the incidence of diploid spermatozoa, which resulted from errors in meiosis II, was elevated significantly compared with the corresponding control value. In contrast, 9 wk of cyclophosphamide treatment induced a significant increase in the frequency of spermatozoa with disomy 4 (Y-4-4) as well as in the aggregate frequency of spermatozoa carrying chromosome 4 or Y disomies. Although the frequency of disomy Y and of disomy 4 of the 0-4-4 type increased by 2-fold and 1.5-fold, respectively, these values were not significantly different than the corresponding control values. Nullisomy 4 was significantly greater following 9 wk of cyclophosphamide treatment than in the concurrent controls; however, this was not different from what was observed after 6 wk of treatment. The incidence of Y-Y-4-4 autodiploid sperm did not differ significantly between treated and control rats. Nevertheless, the overall frequency of numerically abnormal spermatozoa, including all aneuploid and diploid cells, was higher in treated (range, [14] [15] [16] [17] [18] [19] than in control (range, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] by approximately 2-fold (P Ͻ 0.001) following 9 wk of cyclophosphamide treatment.
In a previous study [20] , the frequency of chromosome 4 disomy was significantly higher than that of Y-chromosomal disomy. This was confirmed in the present study (Table 1). The average frequency of chromosome 4 disomy after 6 or 9 wk of cyclophosphamide treatment was significantly greater than that of Y-chromosomal disomy (P Ͻ 0.001). A similar difference (P Ͻ 0.001) was observed when comparing the frequencies of disomy 4 and disomy Y in both control groups. Thus, independent of treatment, disomy 4 was significantly more frequent than disomy Y.
As a result of the rapid advancement of assisted reproductive technologies requiring the selection of germ cells that appear to be most suitable for fertilization, it is of interest to determine the proportion of numerically abnormal cells that are identifiable based on phenotypical anomalies, namely size and shape ( Table 2) . Independent of treatment, the overall number of chromosomally abnormal spermatozoa detected on the basis of phenotypic defects was 64 cells out of a total of 205 chromosomally abnormal cells. Aneuploid spermatozoa that were large in size (Fig. 3, A and  B ) occurred approximately 11-fold more frequently than those cells that presented with shape irregularities. Spermatozoa that were large in size and had simultaneous shape abnormalities (Fig. 3C) presented at a rate approximately 5-fold greater than that for cells with shape defects alone but approximately 2.5-fold less than that for those cells that were only large in size. The percentage of aneuploid cells detected based on atypical appearance was not significantly increased following cyclophosphamide treatment when compared to the corresponding saline values for 6 and 9 wk of treatment (Table 2) . Overall, these results highlight the fact that only a small proportion of aneuploid cells can be identified as a consequence of morphological irregularities, emphasizing the high potential for selection of numerically abnormal spermatozoa in assisted reproduction. Diploid cells (Fig. 2F) , in contrast, were observed to be approximately 2 times the size of normal cells in all cases, suggesting that diploidy can be selected against based on size and, hence, DNA content of the cell.
DISCUSSION
Chronic treatment of male rats with cyclophosphamide before mating results in male-mediated fetal loss and teratogenicity [35, 37, 40] . Evidence of chromosomal anoma- lies, obtained by karyotyping the somatic tissue of malformed offspring fathered by cyclophosphamide-exposed males, suggested a link between the genetic complement and the health of individual progeny [41] . In the current study, we used FISH specific for rat chromosomes Y and 4 in epididymal spermatozoa to measure the chromosome complement directly in the spermatozoa of cyclophosphamide-treated rats. The present data demonstrate that chronic cyclophosphamide treatment, initially exposing either spermatogonia or pachytene spermatocytes (Fig. 1) , induced a germ cell stage-specific increase in the frequency of numerical chromosomal abnormalities. Cyclophosphamide primarily induced chromosomal aneuploidy in germ cells before meiosis, as demonstrated by the increased frequency of aneuploid spermatozoa following 9 wk of treatment.
Aneugenic Effect of Chronic Cyclophosphamide Exposure on Male Germ Cells
Administration of a single dose of cyclophosphamide to male mice, exposing male germ cell stages from spermatogonia to metaphase I [42] or at a time coincident with the premeiotic S phase [33] , resulted in a significant increase in metaphase II hyperhaploidy [33, 42] . Although the observed increases in aneuploidy in cyclophosphamide-damaged spermatocytes were minimal [33] , a statistically significant correlation of metaphase II hyperhaploidy was found with pairing anomalies that may lead to disruptions in the meiotic exchange process and result in a predisposition toward chromosome malsegregation [33, 42] .
To determine the stage specificity of the induction of nondisjunction events as well as to identify the potential genetic risk of the ensuing mature gametes, rats were treated chronically under one of two cyclophosphamide regimes of differing exposure lengths (see Materials and Methods and Fig. 1 ). That aneuploidy was increased when germ cells were first targeted as spermatogonia, but not as pachytene spermatocytes (Table 1) , is consistent with the following hypotheses: First, a critical window exists before pachynema, during which the alkylation by cyclophosphamide interferes with molecular events that are responsible for ensuring faithful chromosome recombination and segregation during meiosis. Second, germ cells with numerical chromosomal defects can develop to mature spermatozoa, thereby introducing the risk of delivering a defective genome to the developing embryo. Germ cells at different stages have differential responses to genetic damage [43, 44] . Although spermatogonia are quite well protected against bifunctional nitrogen mustards, these drugs are highly mutagenic to successive pre-and postmeiotic germ cells [45, 46] . Considered together, previous cytogenetic observations [33, 42] and the current induction of aneuploidy in premeiotic-exposed germ cells suggest that cyclophosphamide acts primarily on preleptotene and zygotene/pachytene stages by interfering with different genes and regulatory proteins functioning in synaptonemal complex formation, crossing-over, and chiasmata formation [47, 48] , affecting the fidelity of subsequent processes of disjunction.
Damaged germ cells may persist because of a decrease in apoptosis [49, 50] ; the dose of cyclophosphamide selected for the present study may not have induced sufficient DNA damage to trigger a significant degree of apoptosis in premeiotic and meiotic cells. Alternatively, repeated, lowdose drug exposure may alter the expression of genes necessary to trigger an apoptotic response [49, 50] or overwhelm protective mechanisms, such as DNA repair [41] . The maintenance of genomic integrity following toxicant exposure largely depends on the capacity of the cells to repair damaged DNA. Cyclophosphamide exposure markedly repressed the expression of genes involved in the nucleotide excision-repair, base excision-repair, and mismatch-repair pathways as well as cell-cycle kinases involved in the meiotic checkpoint after chronic treatment [51] , perhaps increasing susceptibility to genetic damage.
Sex chromosomes generally appear to be particularly susceptible to nondisjunction in male meiosis resulting from failed recombination in the pseudoautosomal region of the XY bivalent [52] . The present study demonstrated that the frequency of spermatozoa with disomy Y was significantly less than the frequency of those with disomy 4 across all groups, confirming the finding of the previous rat aneuploidy baseline study [20] . Chromosome Y disomy is an error that occurs uniquely in the paternal second meiotic division and that might be expected to occur less frequently than autosomal errors resulting from errors in either of the meiotic divisions [20] . Because the incidence of neither disomy Y nor of Y-Y-4-4 autodiploidy was significantly elevated following cyclophosphamide treatment, cyclophosphamide may induce aneuploidy primarily through errors at meiosis I. As such, an increase in the frequency of X-Y-4 would also be predicted. Development of an X chromosome-specific probe would permit us to further examine this issue by revealing the incidence of X-Y-4-4 diploidy caused by failure of meiosis I as well as to further define abnormal genotypes involving the X chromosome.
Aneuploidy in Phenotypically Abnormal Spermatozoa
The incidence of aneuploidy in human spermatozoa is not significantly different between spermatozoa with a normal versus an aberrant head morphology [53, 54] . Conversely, certain morphological abnormalities reflect increased cytogenetic abnormalities in immature germ cells and spermatozoa [55] . In the present study, aneuploidy was associated with phenotypic spermatozoal defects in approximately 27% of cells. Although no clear correlation exists between aneuploidy and morphology, a large spermatozoal head may be reliably associated with a diploid chromosome complement. Yurov et al. [56] found that the majority of human spermatozoa with a large head were diploid, whereas spermatozoa with normal-sized heads were generally haploid. This was also demonstrated in rats by using dualcolor FISH [57] . Consequently, it was suggested that the majority of spermatozoa that are hyperhaploid for chromosome 4, with Y-4-4 and 0-4-4 fluorescent phenotypes, and large in size correspond to diploid cells carrying (X)-Y-4-4 or (X-X)-4-4 genotypes, respectively [57] . We can speculate that a proportion of the observed aneuploidy is caused by diploidy from errors in meiosis I. Most strikingly, a very low proportion of genetically abnormal spermatozoa may be recognized on the basis of phenotype, highlighting the need for genetic and molecular analysis of spermatozoa from males when attempting artificial insemination. Sperm FISH quantitatively measures the level of aneuploidy induction following toxicant exposure; however, the precise mechanism of induction is not fully addressed. The presence of genotoxic damage in rat epididymal spermatozoa, together with the observation that genetically abnormal spermatozoa are capable of fertilization and zygotic development [26] , raise concern regarding a higher risk of adverse male-mediated effects on progeny following chemotherapy with cyclophosphamide.
